The record
Every material change on record
53 material regulatory changes — state legislation, FDA enforcement and compounding actions, and FTC advertising cases. The live feed shows the last 18 months; this is everything, permanently. Each entry links to its own page and, from there, to the primary source.
Background records — single-shipment border refusals and routine facility citations — are on the feed but not here. They are on the record and they are not things a practice acts on; mixing them in would bury the changes that are.
2026 · 28 changes
- Aug 12, 2026FederalFDA Warning Letter: K.C. Pharmaceuticals, Inc (Drugs)
- Aug 7, 2026IllinoisIL HB5000: Health Facilities Planning
- Jul 30, 2026FederalFDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2027
- Jul 8, 2026FederalFDA Warning Letter: Spa De Soleil, Inc. (Drugs)
- Jun 26, 2026FederalFDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
- Jun 23, 2026FederalFDA Warning Letter: ketaminelab.org (Drugs)
- Jun 12, 2026FederalFTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
- Jun 11, 2026FederalFDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
- May 27, 2026FederalFDA recall (Class II): Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, Fl 34108, …
- May 1, 2026FederalFDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
- Apr 23, 2026ColoradoCO SB130: Medical Spas Deceptive Trade Practices
- Apr 22, 2026FederalFDA recall (Class II): Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Bea…
- Apr 8, 2026MaineME LD2201: An Act to Implement Certain Recommendations Related to the Regulatory Review and Approval of Certain Health Care Transactions Involving Private Equity Companies, Hedge Funds or Management Services Organizations from the Commission to Evaluate the Scope of Regulatory Review and Oversight over Health Care Transactions That Impact the Delivery of Health Care Services in the State
- Mar 27, 2026KentuckyKY HB885: an Act relating to cosmetology.
- Mar 18, 2026FederalFDA device recall (Class II): Clarity II Laser System; Model No. 1110200210.
- Mar 13, 2026FloridaFL H1429: Licensure of Medical Spas
- Mar 11, 2026FederalFDA recall (Class II): Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061, …
- Mar 11, 2026FederalFDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- Mar 11, 2026FederalFDA recall (Class II): Semaglutide, For Rx compounding use only, packaged in a) 1g, Ndc 84385-106-01; b) 5g, Ndc 84385-106-02; c) 10g, Ndc 843…
- Mar 5, 2026IndianaIN SB0282: Compounding drugs; registration of medical spas.
- Feb 12, 2026Rhode IslandRI H7721: Establishes the Rhode Island Ban on the Corporate Practice of Medicine Act.
- Feb 10, 2026ArizonaAZ HB4047: Medical spas; licensure; regulation
- Feb 3, 2026MississippiMS SB2544: Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.
- Jan 28, 2026FederalFDA device recall (Class II): Brand Name: Leaseir Product Name: Leaseir Mhr Xcell Model/Catalog Number: Mhr 110-b Software Version: 1.5.0.0 Product D…
- Jan 28, 2026HawaiiHI HB2456: Relating To Drugs For Weight Loss.
- Jan 27, 2026MassachusettsMA H5087: Regulating the operation of medical spas
- Jan 20, 2026IowaIA HSB591: A bill for an act establishing the medical spa oversight Act, and making penalties applicable.
- Jan 7, 2026FederalFDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
2025 · 22 changes
- Dec 16, 2025PennsylvaniaPA HB1881: Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
- Nov 5, 2025FederalFDA recall (Class II): Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeff…
- Nov 5, 2025FederalFDA recall (Class II): Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jef…
- Oct 15, 2025FederalFDA recall (Class II): Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 Nw 2nd Ave Ste 20…
- Oct 15, 2025FederalFDA recall (Class II): Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 Nw 2nd Ave Ste 204 Boca Raton…
- Sep 10, 2025FederalFDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- Aug 13, 2025FederalFDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- Aug 13, 2025FederalFDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
- Jul 30, 2025FederalFDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2026
- Jul 2, 2025FederalFDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- Jul 2, 2025FederalFDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, Co 80…
- Jun 30, 2025Rhode IslandRI H5351: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
- May 7, 2025FederalFDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
- Apr 7, 2025ColoradoCO HB1024: Medical-Aesthetic Services Delegation Disclosures
- Mar 25, 2025North CarolinaNC S570: Prohibit the Corporate Practice of Medicine
- Feb 13, 2025MississippiMS HB1430: Prescription drugs; prohibit licensing boards from prohibiting practitioners from prescribing for off-label use.
- Feb 7, 2025IllinoisIL SB2347: Dfpr-criminal Convictions
- Jan 21, 2025WashingtonWA SB5387: Concerning the corporate practice of medicine.
- Jan 14, 2025South CarolinaSC S0046: Healthcare contracts
- Jan 7, 2025IllinoisIL HB4281: Certified Medical Esthetician
- Jan 7, 2025FederalFDA / Federal Register Notice: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
- Jan 7, 2025FederalFDA / Federal Register Notice: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
2024 · 1 change
2023 · 1 change
- Mar 7, 2023South CarolinaSC H4084: Dental administration of neuromodulators
2021 · 1 change
Regulatory monitoring, not legal, medical, or compliance advice. Every item links its primary source; verify there before acting. Legislative data via LegiScan (CC BY 4.0).